Treatment of Urinary Symptoms in MCAS

Initial Diagnostic Confirmation

The American Gastroenterological Association recommends obtaining baseline serum tryptase and repeating 1-4 hours following symptomatic episodes, with increases of 20% above baseline plus 2 ng/mL confirming mast cell activation 2, 3, 4
The National Comprehensive Cancer Network suggests considering 24-hour urine studies for N-methylhistamine, prostaglandin D2, and 11β-prostaglandin F2α, though these are most useful when serum tryptase is not markedly elevated 5

The American Academy of Allergy, Asthma, and Immunology recommends starting with non-sedating H1 receptor antagonists (cetirizine, fexofenadine) at 2-4 times FDA-approved doses to control symptoms 6, 1
The American Geriatrics Society advises avoiding first-generation H1 antihistamines (diphenhydramine, hydroxyzine) as primary therapy in elderly patients due to cognitive decline and anticholinergic effects 6
The American College of Gastroenterology recommends adding H2 receptor antagonists (famotidine) to enhance symptom control by blocking additional histamine pathways 6, 1
Combined H1 and H2 therapy is more effective than monotherapy for severe symptoms, according to the American College of Allergy, Asthma, and Immunology 1

The American Thoracic Society suggests adding montelukast or zileuton if urinary leukotriene E4 levels are elevated or if inadequate response to antihistamines occurs 6, 1
The American Heart Association recommends considering aspirin therapy if urinary 11β-PGF2α levels are elevated, but with caution due to the risk of paradoxical mast cell activation 6, 1

The American Academy of Allergy, Asthma, and Immunology recommends considering omalizumab for patients with refractory symptoms despite maximal anti-mediator therapy 6, 1
The National Institutes of Health advises reserving systemic corticosteroids for severe refractory symptoms only and tapering as quickly as possible to limit adverse effects 6, 1

The American Gastroenterological Association recommends referring to an allergy specialist or mast cell disease research center when MCAS diagnosis is supported through clinical and/or laboratory features 2, 3, 4
The American College of Allergy, Asthma, and Immunology suggests referring when symptoms remain refractory to first-line therapy or when additional testing or advanced therapies are needed 6, 2, 3, 4

The American Academy of Allergy, Asthma, and Immunology recommends identifying and avoiding specific triggers of mast cell activation (hot water, alcohol, drugs, stress, exercise, hormonal fluctuations, infection, physical stimuli) 7, 6
The National Comprehensive Cancer Network advises carrying 2 epinephrine auto-injectors for potential anaphylactic reactions 5, 1

The American College of Allergy, Asthma, and Immunology recommends measuring mediator levels at baseline and during acute episodes to guide therapy 6
The American Thoracic Society suggests adjusting therapy based on specific mediator elevations: if only histamine products are elevated, focus on antihistamines; if prostaglandins are elevated, consider aspirin 6